Journal cover. (Molecules)
How might the novel coronavirus be prevented from entering a host cell in an effort to thwart infection? A team of biomedical scientists has made a discovery that points to a solution.
The scientists, led by Maurizio Pellecchia in the School of Medicine at the University of California, Riverside, report in the journal Molecules that two proteases — enzymes that break down proteins — located on the surface of host cells and responsible for processing viral entry could be inhibited. Such protease inhibition would prevent SARS-CoV2, the coronavirus responsible for COVID-19, from invading the host cell.
The research is featured as the cover story of the journal (Volume 25, Issue 10).
Spike glycoprotein
The outer surface of coronaviruses contains a critical protein called spike glycoprotein, or S-glycoprotein. Responsible for giving the coronavirus its typical crown shape, the S-glycoprotein is essential for the entry of viral particles into host cells. Host cell proteases, however, must first process or cut this viral surface protein to allow the virus to enter the cells.
Pellecchia’s lab and others have recognized that in addition to a previously identified protease called TMPRSS2, the new SARS-CoV2 coronavirus could also be processed by an additional human protease, called furin, for viral entry.
“The use of the host protease furin for processing is a common mechanism of cell entry by both viral fusion proteins and certain bacterial toxins,” said Pellecchia, a professor of biomedical sciences, who led the research team. “SARS-CoV2 uses this mechanism also. The nature of the ‘proteolytic cleavage’ in its S-glycoprotein can determine whether this virus can be transmitted across species, for example from bats or camels to humans.”
A fusion protein combines the attributes of more than one protein. Proteolytic cleavage refers to the process of breaking the peptide bonds between amino acids in a protein, which results in cutting the protein.
The coronavirus S-glycoprotein contains three cleavage sites that human host proteases process. The exact nature and sequence of these cleavage sites, and their respective processing proteases, can determine the level of pathogenicity and whether the virus can cross species.
Spotlight on inhibitors
Pellecchia explained that the anthrax toxin, similar to SARS-CoV2, requires processing by human furin to infect macrophages, a type of white blood cell. Using anthrax toxin as model system, his team found an inhibitor of both TMPRSS2 and furin in cellular and animal models can efficiently suppress cell entry by the toxin.
A clinical trial with COVID-19 patients recently began using the TMPRSS2 inhibitor camostat.
“We found, however, that camostat is a poor furin inhibitor,” Pellecchia said. “Our current study, therefore, calls for the development of additional protease inhibitors or inhibitor-cocktails that can simultaneously target both TMPRSS2 and furin and suppress SARS-CoV2 from entering the host cell.”
Pellecchia added that until now the presence of a furin cleavage site in SARS-CoV2 had been linked to increased pathogenicity. But genetic elimination of furin in cellular laboratory studies failed to stop viral entry, suggesting TMPRSS2 remains the most relevant protease.
Using peptide sequences from SARS-CoV2 S-glycoprotein, however, his team has now demonstrated the new mutations in this coronavirus strain resulted in efficient and increased processing of viral entry by furin and TMPRSS2.
“In other words, SARS-CoV2, unlike other less pathogenic strains, can more efficiently use both proteases, TMPRSS2 and furin, to start the invasion of host cells,” Pellecchia said. “While TMPRSS2 is more abundant in the lungs, furin is expressed in other organs, perhaps explaining why SARS-CoV2 is capable of invading and damaging multiple organs.”
Pellecchia’s lab has already identified potent and effective preclinical inhibitors of furin and demonstrated these inhibitors could be developed as potential COVID-19 therapeutics, perhaps in combination with drugs such as camostat, the TMPRSS2 inhibitor.
Funding sought
“We are seeking additional funding to pursue the design and development of dual inhibitors that can simultaneously target both TMPRSS2 and furin,” Pellecchia said. “The funding would allow us to explore new possible effective therapeutics against COVID-19 and support studies that could have far reaching applications to ward off possible future pandemics resulting from similar activating mutations in other viral strains.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Suppressing SARS-CoV2
- 11 natural ways to suppress appetite
Manufacturers of appetite suppressant pills make claims about their ability to suppress appetite and promote weight loss. However, the effectiveness of these pills is not known, and they may come ...
- House Republicans say Brazil using claims of 'disinformation' to suppress critics on X
Republicans on the House Select Subcommittee on the Weaponization of the Federal Government report they have a bombshell investigation into the Brazilian government's efforts to suppress critics ...
- 'Suppressing their own votes': GOP operative unloads on RNC's lie-filled robocall
Before joining Raw Story, Brad Reed spent eight years writing about technology at BGR.com and Network World. Prior to that, he wrote freelance stories for political publications such as AlterNet ...
- MAGA operatives behind 2020 voter suppression robocalls will pay up to $1.25 million in penalties
Two right-wing operatives with a history of peddling conspiracy theories are now facing the consequences of orchestrating a more real conspiracy of their own. Jacob Wohl and Jack Burkman agreed to ...
- Operatives must pay up to $1.25 million for robocall scheme to suppress Black votes
Right-wing political operatives Jack Burkman, left, and Jacob Wohl at a news conference in Arlington, Va., in 2019. (Dayna Smith for The Washington Post) Two right-wing political operatives must ...
Go deeper with Google Headlines on:
Suppressing SARS-CoV2
[google_news title=”” keyword=”suppressing SARS-CoV2″ num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Effective therapeutics against COVID-19
- Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights
Launched PEMGARDA™ in the U.S. for COVID-19 pre-exposure prophylaxis (PrEP) in certain adults and adolescents with moderate-to-severe immune ...
- New vaccine effective against coronaviruses that haven't even emerged yet
Researchers have developed a new vaccine technology that has been shown in mice to provide protection against a broad range of coronaviruses with potential for future disease outbreaks -- including ...
- It is vital we agree a global pact on pandemics to prevent the devastation caused by covid-19
The overarching lesson from the covid-19 pandemic — one that we learned the hard way — is that no one is safe anywhere until everyone is safe everywhere. Global health security is possible only if we ...
- Q1 2024 Anika Therapeutics Inc Earnings Call
Mark Namaroff; VP of Investor Relations, ESG, and Corporate Communications; Anika Therapeutics, Inc. Cheryl Blanchard; President and CEO; Anika Therapeutics, Inc ...
- Novel bispecific antibodies show promise against evolving SARS-CoV-2 variants
Researchers developed bispecific antibodies targeting both the N-terminal and receptor binding domains of SARS-CoV-2, demonstrating significant neutralization across various Omicron variants, ...
Go deeper with Google Headlines on:
Effective therapeutics against COVID-19
[google_news title=”” keyword=”effective therapeutics against COVID-19″ num_posts=”5″ blurb_length=”0″ show_thumb=”left”]